BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31439673)

  • 1. Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation.
    Peiris MN; Meyer AN; Nelson KN; Bisom-Rapp EW; Donoghue DJ
    Haematologica; 2020 May; 105(5):1262-1273. PubMed ID: 31439673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.
    Jin Y; Zhen Y; Haugsten EM; Wiedlocha A
    Cell Signal; 2011 Nov; 23(11):1758-66. PubMed ID: 21745565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome.
    Chong Y; Liu Y; Lu S; Cai B; Qin H; Chang CS; Ren M; Cowell JK; Hu T
    Int J Cancer; 2020 Apr; 146(8):2243-2254. PubMed ID: 31525277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
    Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
    Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
    Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
    Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of two rare BCR-FGFR1
    Barnes EJ; Leonard J; Medeiros BC; Druker BJ; Tognon CE
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31980503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
    Ren M; Qin H; Ren R; Tidwell J; Cowell JK
    Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.
    Peiris MN; Meyer AN; Warda D; Campos AR; Donoghue DJ
    Oncotarget; 2022; 13():659-676. PubMed ID: 35574218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
    Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
    Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review.
    Washburn E; Bayerl MG; Ketterling RP; Malysz J
    Cancer Genet; 2021 Nov; 258-259():69-73. PubMed ID: 34551378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.
    Morishige S; Oku E; Takata Y; Kimura Y; Arakawa F; Seki R; Imamura R; Osaki K; Hashiguchi M; Yakushiji K; Mizuno S; Yoshimoto K; Nagafuji K; Ohshima K; Okamura T
    Acta Haematol; 2013; 129(2):83-9. PubMed ID: 23171834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.
    Hu T; Chong Y; Lu S; Qin H; Ren M; Savage NM; Chang CS; Cowell JK
    Cancer Res; 2019 Jan; 79(1):114-124. PubMed ID: 30413411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
    Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
    Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
    Roumiantsev S; Krause DS; Neumann CA; Dimitri CA; Asiedu F; Cross NC; Van Etten RA
    Cancer Cell; 2004 Mar; 5(3):287-98. PubMed ID: 15050920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase.
    Hu T; Chong Y; Qin H; Kitamura E; Chang CS; Silva J; Ren M; Cowell JK
    Oncogene; 2018 Apr; 37(14):1926-1938. PubMed ID: 29367757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of a patient characterized by t(8;22)(p11;q11) and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation.
    Chen X; Huang L; Zheng C; Wang Z
    Hematology; 2021 Dec; 26(1):691-696. PubMed ID: 34493159
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of acute myelogenous leukaemia characterised by the BCR-FGFR1 translocation.
    Matikas A; Tzannou I; Oikonomopoulou D; Bakiri M
    BMJ Case Rep; 2013 Mar; 2013():. PubMed ID: 23519513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.
    Baldazzi C; Iacobucci I; Luatti S; Ottaviani E; Marzocchi G; Paolini S; Stacchini M; Papayannidis C; Gamberini C; Martinelli G; Baccarani M; Testoni N
    Leuk Res; 2010 Oct; 34(10):e282-5. PubMed ID: 20594995
    [No Abstract]   [Full Text] [Related]  

  • 19. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
    Wasag B; Lierman E; Meeus P; Cools J; Vandenberghe P
    Haematologica; 2011 Jun; 96(6):922-6. PubMed ID: 21330321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
    Murati A; Arnoulet C; Lafage-Pochitaloff M; Adélaide J; Derré M; Slama B; Delaval B; Popovici C; Vey N; Xerri L; Mozziconacci MJ; Boulat O; Sainty D; Birnbaum D; Chaffanet M
    Int J Oncol; 2005 Jun; 26(6):1485-92. PubMed ID: 15870860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.